162641-16-9

HQL-79 is a selective PGE synthase inhibitor.

HQL 79 is an orally active anti-allergic agent th at acts as an antagonist for histamine H1 receptors (H1R)eliciting anti-asthmatic effects. It interacts with prostaglandin (PG) D synthase (H-PGDS) in the catalytic region. It may be potential lead due to its H-PGDS inhibition to tre at allergies.''HQL-79 is a selective inhibtor of hematopoietic prostaglandin D (PGD) synthaseone of two synthases involved in the production of Prostaglandin D2 (PGD2) from arachidonic acid. PGD2 is a lipid signaling moleculewhich activates two receptorsDP1 involved in centrally mediated processes such as sleep and pain and DP2 involved and inflammation. The two PGD synthases involved in its synthesis are lipocalin-type (L-PGDS) and hematopoietic (H-PDGS)which acts to form PGD2 in mast cellsTh2 cellsmicrogliaand other inflammatory cells/tissues. HQL-79 selectively inhibited the activity of recombinant H-PGDS with an IC50 of 6 μM and ha

Store at RT